Palbace 125 mg Capsule
  1. Home
  2. Pharma Products
  3. Pfizer Ltd
  4. Palbace 125 mg Capsule

Palbace 125 mg Capsule

Palbace 125 mg Capsule contains palbociclib, a targeted anticancer medicine used to treat certain hormone receptor-positive, HER2-negative breast cancers. It works by inhibiting CDK4 and CDK6 proteins that help cancer cells divide and grow. The capsule is taken orally under the supervision of a qualified healthcare professional.

BUY NOW

Category

Palbace 125 mg Capsule contains 125 mg of palbociclib and is formulated for oral administration. It is used in combination with endocrine therapy for hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. The recommended palbociclib regimen is 125 mg once daily for 21 consecutive days followed by 7 days without treatment, forming a 28-day cycle. Complete blood counts should be monitored regularly during treatment because dose interruptions or reductions may be required for blood-related adverse effects.

Technical Specification

Specification Details
Active Ingredient Palbociclib 125 mg
Dosage Form Capsule
Therapeutic Class Cyclin-Dependent Kinase Inhibitor
Main Indication HR-Positive, HER2-Negative Breast Cancer
Route of Administration Oral
Storage Below 30°C

Product Also Known As

Palbace 125 mg Capsule, Palbace 125 mg, Palbociclib 125 mg Capsule, Palbociclib 125 mg, Palbociclib Hard Capsule, Palbociclib Breast Cancer Capsule